Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 126700
Published online Nov 24, 2026. doi: 10.5306/wjco.126700
Published online Nov 24, 2026. doi: 10.5306/wjco.126700
Table 1 Molecular signatures of gastric cancer
| Molecular | Behavior | Recurrence | Notes |
| MSI | Best prognosis | Low risk of recurrence | Resistant to chemotherapy |
| PD-L1+ | Low risk of recurrence | Sensitive to immunotherapy | |
| MSS/EMT- (EBV+) | Intermediate prognosis | Middle risk of recurrence | Sensitive to chemo/immunotherapy |
| HER2+ | Intermediate prognosis | Middle risk of recurrence | Sensitive to targeted therapy |
| MSS/EMT+ | Worst prognosis | High risk of recurrence |
Table 2 Definitions of oligometastatic disease
| Consensus | Study | Appropriate candidates for conversion therapy |
| OMEC | Kroese et al[50] | Limited to 1 organ with ≤ 3 metastases, or involvement of 1 extra-regional lymph node station |
| KINGCA | Kim et al[54] | Limited to 1 organ, or involvement of 1 extra-regional lymph node station or positive peritoneal cytology (Yoshida 1) |
| Bertinoro | Morgagni et al[52] | ≤ 3 resectable liver or lung metastases (excluded bones), or involvement of para-aortic nodes, or peritoneal cancer index ≤ 6 |
- Citation: Carbone L, Marrelli D, Barbato B, Visani A, Corso G, Roviello F. Specific molecular signature redefines the role of posterior and para-aortic (D2 plus) lymphadenectomy in gastric cancer: Rethinking surgical indications. World J Clin Oncol 2026; 17(11): 126700
- URL: https://www.wjgnet.com/2218-4333/full/v17/i11/126700.htm
- DOI: https://dx.doi.org/10.5306/wjco.126700